Literature DB >> 24533175

SAR and Lead Optimization of an HIV-1 Vif-APOBEC3G Axis Inhibitor.

Idrees Mohammed1, Maloy K Parai1, Xinpeng Jiang1, Natalia Sharova2, Gatikrushna Singh1, Mario Stevenson2, Tariq M Rana1.   

Abstract

We describe structure-activity relationship and optimization studies of RN-18, an HIV-1 Vif-APOBEC3G axis inhibitor. Targeted modifications of RN-18 ring-C, ring-B, ring-A, bridge A-B, and bridge B-C were performed to identify the crucial structural features, which generated new inhibitors with similar (4g and 4i) and improved (5, 8b, and 11) activities. Two potent water-soluble RN-18 analogues, 17 and 19, are also disclosed, and we describe the results of pharmacological studies with compound 19. The findings described here will be useful in the development of more potent Vif inhibitors and in the design of probes to identify the target protein of RN-18 and its analogues.

Entities:  

Keywords:  HIV-1 Vif-APOBEC3G axis inhibition; RN-18; pharmacological studies; structure-activity relationship and optimization

Year:  2012        PMID: 24533175      PMCID: PMC3922209          DOI: 10.1021/ml300037k

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  11 in total

1.  A general, efficient, and inexpensive catalyst system for the coupling of aryl iodides and thiols.

Authors:  Fuk Yee Kwong; Stephen L Buchwald
Journal:  Org Lett       Date:  2002-10-03       Impact factor: 6.005

2.  A mild and selective method for the hydrolysis of esters with trimethyltin hydroxide.

Authors:  K C Nicolaou; Anthony A Estrada; Mark Zak; Sang Hyup Lee; Brian S Safina
Journal:  Angew Chem Int Ed Engl       Date:  2005-02-18       Impact factor: 15.336

3.  Difluoromethylbenzoxazole pyrimidine thioether derivatives: a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

Authors:  Jérémie Boyer; Eric Arnoult; Maurice Médebielle; Jérôme Guillemont; Johan Unge; Dirk Jochmans
Journal:  J Med Chem       Date:  2011-11-04       Impact factor: 7.446

4.  Small-molecule inhibition of HIV-1 Vif.

Authors:  Robin Nathans; Hong Cao; Natalia Sharova; Akbar Ali; Mark Sharkey; Ruzena Stranska; Mario Stevenson; Tariq M Rana
Journal:  Nat Biotechnol       Date:  2008-09-21       Impact factor: 54.908

5.  Decomposing the energetic impact of drug resistant mutations in HIV-1 protease on binding DRV.

Authors:  Yufeng Cai; Celia A Schiffer
Journal:  J Chem Theory Comput       Date:  2010-04-13       Impact factor: 6.006

6.  Design of substituted bis-Tetrahydrofuran (bis-THF)-derived Potent HIV-1 Protease Inhibitors, Protein-ligand X-ray Structure, and Convenient Syntheses of bis-THF and Substituted bis-THF Ligands.

Authors:  Arun K Ghosh; Cuthbert D Martyr; Melinda Steffey; Yuan-Fang Wang; Johnson Agniswamy; Masayuki Amano; Irene T Weber; Hiroaki Mitsuya
Journal:  ACS Med Chem Lett       Date:  2011-04-14       Impact factor: 4.345

7.  Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones.

Authors:  Akbar Ali; G S Kiran Kumar Reddy; Madhavi N L Nalam; Saima Ghafoor Anjum; Hong Cao; Celia A Schiffer; Tariq M Rana
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

8.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

9.  Ligand-free copper-catalyzed C-S coupling of aryl iodides and thiols.

Authors:  Elena Sperotto; Gerard P M van Klink; Johannes G de Vries; Gerard van Koten
Journal:  J Org Chem       Date:  2008-06-21       Impact factor: 4.354

Review 10.  Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.

Authors:  Taisuke Izumi; Kotaro Shirakawa; Akifumi Takaori-Kondo
Journal:  Mini Rev Med Chem       Date:  2008-03       Impact factor: 3.862

View more
  11 in total

Review 1.  Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.

Authors:  Shikha Kumari; Angelica V Carmona; Amit K Tiwari; Paul C Trippier
Journal:  J Med Chem       Date:  2020-08-04       Impact factor: 7.446

2.  Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors.

Authors:  Wenlin Huang; Tao Zuo; Hongwei Jin; Zhenming Liu; Zhenjun Yang; Xianghui Yu; Liangren Zhang; Lihe Zhang
Journal:  Mol Divers       Date:  2013-02-03       Impact factor: 2.943

3.  1,2,3-Triazoles as Amide Bioisosteres: Discovery of a New Class of Potent HIV-1 Vif Antagonists.

Authors:  Idrees Mohammed; Indrasena Reddy Kummetha; Gatikrushna Singh; Natalia Sharova; Gianluigi Lichinchi; Jason Dang; Mario Stevenson; Tariq M Rana
Journal:  J Med Chem       Date:  2016-08-10       Impact factor: 7.446

Review 4.  APOBEC Enzymes as Targets for Virus and Cancer Therapy.

Authors:  Margaret E Olson; Reuben S Harris; Daniel A Harki
Journal:  Cell Chem Biol       Date:  2017-11-16       Impact factor: 8.116

Review 5.  A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation.

Authors:  Ryan P Bennett; Jason D Salter; Harold C Smith
Journal:  Trends Mol Med       Date:  2018-03-30       Impact factor: 11.951

6.  Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold.

Authors:  Margaret E Olson; Ming Li; Reuben S Harris; Daniel A Harki
Journal:  ChemMedChem       Date:  2012-11-23       Impact factor: 3.466

Review 7.  HIV accessory proteins versus host restriction factors.

Authors:  Klaus Strebel
Journal:  Curr Opin Virol       Date:  2013-11-15       Impact factor: 7.090

Review 8.  Tailored therapeutics based on 1,2,3-1H-triazoles: a mini review.

Authors:  Parteek Prasher; Mousmee Sharma
Journal:  Medchemcomm       Date:  2019-05-14       Impact factor: 3.597

9.  Host APOBEC3G protein inhibits HCV replication through direct binding at NS3.

Authors:  Yan-Ping Zhu; Zong-Gen Peng; Zhou-Yi Wu; Jian-Rui Li; Meng-Hao Huang; Shu-Yi Si; Jian-Dong Jiang
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 10.  Suppression of APOBEC3-mediated restriction of HIV-1 by Vif.

Authors:  Yuqing Feng; Tayyba T Baig; Robin P Love; Linda Chelico
Journal:  Front Microbiol       Date:  2014-08-26       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.